martes, 4 de noviembre de 2014

National Guideline Clearinghouse | Indications of DXA in women younger than 65 yr and men younger than 70 yr: the 2013 official positions.

FULL-TEXT ►

National Guideline Clearinghouse | Indications of DXA in women younger than 65 yr and men younger than 70 yr: the 2013 official positions.

International Society for Clinical Densitometry

Guideline Title

Indications of DXA in women younger than 65 yr and men younger than 70 yr: the 2013 official positions.

Bibliographic Source(s)

Malabanan AO, Rosen HN, Vokes TJ, Deal CL, Alele JD, Olenginski TP, Schousboe JT. Indications of DXA in women younger than 65 yr and men younger than 70 yr: the 2013 official positions. J Clin Densitom. 2013 Oct-Dec;16(4):467-71. [25 references]PubMed External Web Site Policy

Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: Simonelli C, Adler RA, Blake GM, Caudill JP, Khan A, Leib E, Maricic M, Prior JC, Eis SR, Rosen C, Kendler DL. Dual-energy x-ray absorptiometry technical issues: the 2007 ISCD official positions. J Clin Densitom. 2008 Jan-Mar;11(1):109-22.

-.-

Indications of DXA in women younger than 65 yr and men younger than... - PubMed - NCBI

2013 Oct-Dec;16(4):467-71. doi: 10.1016/j.jocd.2013.08.002. Epub 2013 Sep 20.

Indications of DXA in women younger than 65 yr and men younger than 70 yr: the 2013 Official Positions.

Malabanan AO1, Rosen HN, Vokes TJ, Deal CL, Alele JD, Olenginski TP, Schousboe JT.

Author information

Abstract

Dual-energy X-ray absorptiometry (DXA) is the method of choice to assess fracture risk for women 65 yr and older and men 70 yr and older. The 2007 International Society for Clinical Densitometry Official Positions had developed guidelines for assessing bone density in younger women during and after the menopausal transition and in men 50-69 yr and the 2008 National Osteoporosis Foundation (NOF) guidelines recommended testing in postmenopausal women younger than 65 yr and men 50-69 yr only in the presence of clinical risk factors. The purpose of the 2013 DXA Task Force was to reassess the NOF guidelines for ordering DXA in postmenopausal women younger than 65 yr and men 50-69 yr. The Task Force reviewed the literature published since the 2007 Position Development Conference and 2008 NOF, reviewing clinical decision rules such as the Osteoporosis Screening Tool and FRAX and sought to keep recommendations simple to remember and implement. Based on this assessment, the NOF guidelines were endorsed; DXA was recommended in those postmenopausal women younger than 65 yr and men 50-69 yr only in the presence of clinical risk factors for low bone mass, such as low body weight, prior fracture, high-risk medication use, or a disease or condition associated with bone loss.